VEGF、VEGFR在卵巢癌中的表达及其临床意义

Expressions of vascular endothelial growth factor and its receptors in epithelial ovarian carcinoma and their clinical significance

目的：探讨血管内皮生长因子（VEGF）及其受体（VEGFR：fit-1和KDR）在卵巢癌中的表达及临床意义。方法：采用免疫组织化学SP法检测VEGF及VEGFR在45例卵巢癌中的表达情况，并进行相关的临床病理因素分析。结果：45倒卵巢癌中VEGF、fit-l和KDR阳性表达率分别为86．7％。68．9％，88．9％。Ⅲ～Ⅳ期卵巢癌中VEGF强阳性表达率93．5％（29／31）高于Ⅰ～Ⅱ期卵巢癌35．7％（5／14）（P=0．001）。淋巴结转移阳性组中VEGF强阳性表达率69．2％（9／13）高于淋巴结转移阴性组27．8％（5／18）（P〈0．05）。随着卵巢癌临床分期、病理分级、腹水量及残瘤组织的增加，VEGF阳性表达率升高（P〈0.05），而不同组织类型卵巢癌中，VEGF阳性表达率无明显差异（P〉0．05）。结论：VEGF与卵巢癌发展有关，能促进肿瘤生长、局部侵袭及远处转移。

Objective：To determine the expression of vascular endothelial growth factor （VEGF） and its receptors （flt-1 and KDR） in ovarian cancer. Methods：The expressions of VEGF and VEGFR were evaluated in 45 cases of epithelial ovarian cancer by immunohistochemical SP method. The relationship between the expression of VEGF and VEGFR and some clinicopathologic parameters was analyzed. Results： Positive immunostaining rates of VEGF, flt-1, and KDR were 86.7% （ 39/45 ）, 68. 9% （ 31/ 45）, and 88.9%（40/45） ,respectively. Positive immunostaining rates of VEGF was much higher in Ⅲ-Ⅳ stage of ovarian cancer than that in Ⅰ-Ⅱ stage （93.5% vs 35.7%,P=0.001）. VEGF positive immunostaining was observed more frequently in patients with the lymph node metastasis than those without lymph node metastasis （69.2% vs 27.8%, P（0.05）. The difference in VEGF expression was not significant in different histological types of ovarian cancer. VEGF positive patients showed poor prognosis than VEGF-negative patients. Conclusion：There is a close relationship between VEGF expression and epithelial ovarian cancer progression. VEGF could accelerate growth,local invasion, and metastasis of ovarian cancer.